ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 4 for:    maat pharma

Treatment of Steroid Refractory Gastro-intestinal Acute GVHD afteR AllogeneiC HSCT With fEcal Microbiota tranSfer (HERACLES)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03359980
Recruitment Status : Not yet recruiting
First Posted : December 2, 2017
Last Update Posted : December 4, 2017
Sponsor:
Information provided by (Responsible Party):
MaaT Pharma

Brief Summary:
Patients who have a gastrointestinal acute Graft versus host disease (GVHD) received a first-line standard treatment of corticosteroids. For patients who do not respond or progress after an initial response have a high mortality. There is an interest in identifying effective second line therapy for these patients corticosteroid-resistant acute GVHD. Fecal microbiota transfer might be a beneficial treatment in this clinical situation with a poor prognosis and limited therapeutic options.

Condition or disease Intervention/treatment Phase
Fecal Microbiota Transplantation Drug: fecal microbiota transfer Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 32 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Treatment of Steroid Refractory Gastro-intestinal Acute Graft-versus-Host disEase afteR AllogeneiC Hematopoietic Stem celL Transplantation With fEcal Microbiota tranSfer
Estimated Study Start Date : March 2018
Estimated Primary Completion Date : March 2019
Estimated Study Completion Date : September 2019


Arm Intervention/treatment
Experimental: treated patients
Treated with Fecal Microbiota Transfer (FMT)
Drug: fecal microbiota transfer
transfer of fecal microbiota from healthy donor to the patients



Primary Outcome Measures :
  1. Efficacy of FMT in the treatment of Steroid Refractory -Gastro-intestinal Acute GVHD (SR-GI-aGVHD) at D28 post inclusion [ Time Frame: up to 4 weeks post inclusion ]
    Proportion of patients achieving GI and overall GVHD response by D28, defined as Complete response (CR) or Very Good Partial Response (VGPR)


Secondary Outcome Measures :
  1. Safety of FMT in patients with SR-GI-aGVHD [ Time Frame: through study completion, an average of six months ]
    The overall safety of the study will be evaluated with the incidence of all Adverse Events (AEs) and Serious Adverse Events (SAEs) (frequency, grade, relationship) throughout the study period

  2. Number of patients with infectious disorders [ Time Frame: through study completion, an average of six months ]
    Evaluation of FMT activity on infectious disorders

  3. Number of multidrug resistant bacteria in faeces [ Time Frame: through study completion, an average of six months ]
    Evaluation of FMT activity on multidrug-resistant bacteria (MDRB) carriage

  4. Number of patients with Chronic GVHD [ Time Frame: through study completion, an average of six months ]
    Chronic GVHD expression



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients who develop a first episode of Stage 3 or 4 Gastro-intestinal Acute Graft-versus-Host (GI-aGVHD) with gut predominance (Przepiorka D, 1995), resistant to a first line therapy with steroids (lack of improvement after 5 days or progression after 3 days of treatment with corticosteroids at 2 mg/Kg methylprednisolone equivalent dose) (SR GI-aGVHD)
  • Age ≥ 18 years old
  • Allogeneic Hematopoietic stem cell transplantation (Allo-HSCT) with any type of donor, stem cell source, GVHD prophylaxis or conditioning regimen
  • Patients able to have a minimum of 12 hours discontinuation of systemic antibiotics in order to perform the allogeneic FMT (for patient who received antibiotics MaaT Pharma advises against the use of antibiotics (commonly used) with significant digestive excretion (for example but not limited to: metronidazol, ceftriaxone, tazocillin, levofloxacin))
  • Signature of informed and written consent by the subject or by the subject's legally acceptable representative

Exclusion Criteria:

  • Grade IV hyper-acute GVHD as defined by the MD Anderson's criteria (Saliba RM, 2007)
  • Late onset aGVHD as defined by the National Institutes of Health (NIH) Consensus Criteria (Jagasia MH, 2015)
  • Overlap chronic GVHD as defined by the NIH Consensus Criteria (Jagasia MH, 2015)
  • Acute GVHD after donor lymphocytes infusion (DLI)
  • Relapsed/persistent malignancy requiring rapid immune suppression withdrawal
  • Active uncontrolled infection according to the attending physician
  • Other systemic drugs than corticosteroids for GVHD treatment (including extra-corporeal photopheresis). Drugs already being used for GVHD prevention (eg. calcineurin inhibitors) are allowed.
  • Absolute neutrophil count < 0.5 x 109 /L
  • Absolute platelet count < 10 000
  • Patient Epstein-Barr Virus (EBV) negative
  • Evidence of toxic megacolon or gastrointestinal perforation on abdominal X-ray
  • Known allergy or intolerance to trehalose or maltodextrin or latex
  • Pregnancy: positive urinary or blood test in female of childbearing potential; lactation; absence of effective contraceptive method for female of childbearing potential
  • Other ongoing interventional protocol that might interfere with the current study primary endpoint.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03359980


Contacts
Contact: David Salako 09 72 60 77 98 dsalako@maat-pharma.com
Contact: Emilie Plantamura 04 28 29 14 05 eplantamura@maat-pharma.com

Sponsors and Collaborators
MaaT Pharma
Investigators
Principal Investigator: Florent Malard Hôpital Saint Antoine - PARIS

Responsible Party: MaaT Pharma
ClinicalTrials.gov Identifier: NCT03359980     History of Changes
Other Study ID Numbers: MPOH03
First Posted: December 2, 2017    Key Record Dates
Last Update Posted: December 4, 2017
Last Verified: November 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No